Osiris Therapeutics, Inc. (OSIR) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts OSIR Hot Sheet
Price: $18.99 --0%
Financial Fact:
Weighted average common shares (basic) (in shares): 34.44M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Weighted average common shares (basic) (in shares): 34.44M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Osiris Therapeutics, Inc. (NASDAQ: OSIR) reported Q2 EPS of $0.05, $0.07 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $10.4 million versus the consensus estimate of $10.54 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- First Citizens Bancshares (FCNCA) reported Q3 EPS
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
